ProCE Banner Activity

The Latest Evidence on Selective RET Inhibition in Advanced RET Fusion–Positive NSCLC

Slideset Download
Download these slides from a CCO Live Webinar to review the latest clinical data informing optimal treatment of advanced RET fusion–positive NSCLC, including monitoring for and managing common adverse events with new-generation, selective RET inhibitors.

Released: March 16, 2021

Expiration: March 15, 2022

Share

Faculty

Karen L. Reckamp

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California